The device behind the data
GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
Long-term results you can trust
U.S. Pivotal Clinical Trials: Five year data across ALL etiologies.
Real-world data
SURPASS† Registry results
GREAT data highlights through three years1 across ALL etiologies
5-year Outcomes: U.S. IDE Clinical Trial, Thoracic Aortic Aneurysm
William Jordan, M.D., National Principal Investigator shares his views on the clinical outcomes
5-year Outcomes: U.S. IDE Clinical Trial, Traumatic Aortic Transection
Mark Farber, M.D., National Principal Investigator provides his perspective on key study outcomes
Time-tested innovation
* Migrations are reported as those requiring reintervention.
† Rates are based on physician experience as reported for 127 subjects in Europe within a 30 day follow-up period. European-Post Approval Registry: Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System. (data on file 2017; W.L. Gore & Associates, Inc; Flagstaff, AZ.)
‡ Note: Only serious endoleaks are reported in GREAT (i.e., requiring reintervention).
- W. L. Gore & Associates. 'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation. Bethesda, MD: National Library of Medicine; 2012. Available from: NLM Identifier: NCT01658787. Published August 7, 2012. Updated: September 29, 2021. Accessed June 7, 2022. https://clinicaltrials.gov/ct2/show/NCT01658787
Related to this product
View product brochure
See how
INDICATIONS FOR USE IN THE U.S.: The GORE® TAG® Conformable Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: isolated lesions in patients who have appropriate anatomy, including: adequate iliac/femoral access, aortic inner diameter in the range of 16-42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac/femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16-42 mm. CONTRAINDICATIONS: Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
24AR1014-en01